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We report a BIN1-related CNM family with unusual clinical phenotype. The
proband, a 56-year-old man suffered of lower limbs myalgia since the age of 52.
Clinical examination showed short stature, mild symmetric eyelid ptosis
without ophthalmoplegia, scapular winging and Achilles tendon retraction. A
muscle weakness was not noted. CK levels were up to 350 UI/L. Deltoid muscle
biopsy showed nuclear centralization and clustering, deep sarcolemmal
invaginations and type 1 fiber hypotrophy. Whole body MRI revealed fatty
infiltration of posterior legs compartments, lumbar paraspinal and serratus
muscles. Myotonic dystrophy type1 and 2, Pompe disease and MTM1 and
DNM2-related CNM were ruled out. By sequencing BIN1, we identified a
heterozygous pathogenic mutation [c.107C > A (p.A36E)], and we demonstrate
that the mutation strongly impairs the membrane tubulation property of the
protein. One affected sister carried the same mutation. Her clinical examination
and muscle MRI revealed a similar phenotype. Our findings expand the clinical
and genetic spectrum of the autosomal dominant CNM associated with BIN1
mutations.
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G.P.298
Non-invasive NMR study of the mouse model for centronuclear myopathy
with mutation in the dynamin-2 gene
A. Martins Bach *,1, B. Matot 2, C. Wary 2, M. Bitoun 2, M. Vaizof 3, P. Carlier 2
1 University of São Paulo/Institute of Myologie, Rua do Matão – Travessa 13,
no. 106 – Cidade Universitária, Prédio do Centro de Estudos do Genoma
Humano, São Paulo, Brazil; 2 Institute of Myology, Paris, France; 3 University
of São Paulo/Institute of Myologie, Rua do Matão – Travessa 13, no. 106 –
Cidade Universitária, Prédio do Centro de Estudos do Genoma Humano,
05508-090, Brazil
Centronuclear myopathies are a group of non-dystrophic congenital
myopathies characterized by the altered positioning of the nuclei in muscle
fibers without extensive muscle degeneration and regeneration. The knock-in
KI-Dnm2R465W mouse (Dnm2) models the autosomal dominant centronuclear
myopathy with the most frequent mutation in DNM2 in patients. Different from
human, this model presents only strength reduction and atrophy, with very few
histological alterations. The objective of this study was to non-invasively
characterize Dnm2 mice with nuclear magnetic resonance (NMR), comparing
NMR results to histological findings. For NMR, 16 Dnm2 and 13 wild-type
(WT) mice were evaluated at 3 or 6 months of age, while 4 Dnm2 and 2 WT
mice were evaluated histologically. The NMR study included anatomical
evaluation and muscle T1 and T2 measurements, performed in a 4.7 T
magnet, under isoflurane anesthesia. Despite the similar body weight, atrophy
could be detected in Dnm2 mice by comparing the cross-section of the
caudal limb normalized by tibia length (CSA/Lt: Dnm2 = 2.7 ± 0.3 mm,
WT = 3.0 ± 0.2 mm, p < 0.001). No differences were observed for muscle T1 in
the comparison between Dnm2 and WT mice, for both ages. Muscle T2 was
increased in Dnm2 mice for both ages (T2: Dnm2–3m: 31.8 ± 1.4 ms, WT-3m:
30.2 ± 1.5 ms, p < 0.05; Dnm2–6m: 31.5 ± 1.1 ms, WT-6m: 30.3 ± 1.4,
p < 0.05). Even if this mouse model has a mild phenotype, this non-invasive
NMR study could identify muscle atrophy and increased muscle T2 in the
heterozygous Dnm2 mice. We hypothesize that the increased muscle T2 was
related to altered intracellular organization, due to the absence of pathological
alterations usually related to increased muscle T2, such as necrosis and
inflammation. These results indicate that NMR, especially T2 relaxometry, is
sensitive enough to identify alterations in a pre-clinical stage in the
centronuclear myopathy model, the heterozygous Dnm2 mouse.
http://dx.doi.org/10.1016/j.nmd.2015.06.322
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Centronuclear myopathy (CNM) is a rare congenital myopathy
characterized by centrally located nuclei in most of its muscle fibers. DNM2 is
most commonly found assuming autosomal dominant inheritance pattern.
Clinically, DNM2-related CNM typically shows distal dominant muscle
atrophy, ptosis, ophthalmoplegia and contracture. Here we report a first Korean
family diagnosed as DNM2-related CNM without ocular symptoms. A 48 year
old Korean male presented with slowly progressive weakness since 20s. His
weakness progressed and at the age of 40 he was unable to climb stairs. His
daughter also had a mild myopathic elongated face and she was unable to
perform a tip-toe gait. With mild elevation of creatine kinase, the muscle
magnetic resonance imaging showed an extensive fatty infiltration in the
posterior thigh and distal leg muscles. Muscle biopsy was performed and it
illustrated a numerous number of central nuclei in most of the muscle fibers
with disrupted myofibril that was compatible with a typical centronuclear
myopathy. Genetic analysis of DNM2 revealed a first western prototypic
pathogenic mutation in the middle domain of DNM2 (p.R465W). The
Caucasian studies reported a high prevalence rate of ptosis and
ophthalmoplegia with early onset and it correlated with the severity of the
disease. However, Asian reports show a low prevalence of ocular symptoms in
DNM2-related CNM patients and patients who had ocular symptoms were of
late onset. The p.R465W is one of the most commonly found mutations in the
western countries and all of them had ocular symptoms. However our proband
and his daughter had no ocular symptoms despite the identical mutation.
Therefore clinical findings in DNM2-related CNM can be heterogeneous,
probably due to an ethnic difference that needs to be further elucidated. Also,
this is the first Korean familial case in comparison to a recent Korean study that
reported only sporadic cases.
http://dx.doi.org/10.1016/j.nmd.2015.06.323
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